Forget Aurora Cannabis (TSX:ACB) and Buy This Pot Stock Instead!

Is it time to look beyond companies such as Aurora Cannabis (TSX:ACB)?

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of marijuana giant Aurora Cannabis (TSX:ACB)(NYSE:ACB) continues to remain volatile this month. ACB stock gained 153% between November 4 and November 9. However, it has since declined 38% to close trading at $9.18 yesterday.

Pot stocks, including Aurora, gained momentum on the back of a Joe Biden win. The president-elect is likely to decriminalize or even legalize marijuana in the U.S. in the near future. This will increase the total addressable market for Canadian cannabis companies that are grappling with lower-than-expected sales.

However, Aurora continues to be impacted by a slew of structural issues that include a bloated balance sheet, negative profit margins, and high inventory levels. It continues to raise equity capital in order to boost liquidity, but this has also diluted shareholder wealth significantly.

In the September quarter, Aurora reported a 10% year-over-year decline in sales, while its net loss stood at $107 million. It burned $93 million in cash in the fiscal first quarter of 2021 and announced plans to raise US$150 million by selling 20 million new shares.

Aurora stock is down 71% in 2020

Aurora stock continues to disappoint investors and is down 71% year to date. Though the revenue decline in Q1 can be attributed to its divesture of non-core assets, the company’s net cannabis sales were down 4% year over year. This indicates Aurora Cannabis is losing market share to other players, which will make investors wary.

Aurora aims to generate a positive EBITDA in Q2, but even if it achieves this goal, the company will rely on cost optimization rather than top-line growth. Further, ACB also needs to deliver a positive free cash flow in fiscal 2021 or it will continue to issue equity shares impacting its stock price negatively.

This multi-state operator in the U.S. is a top cannabis bet

While Aurora Cannabis continues to disappoint investors, one marijuana stock has easily outperformed peers in 2020. Shares of Green Thumb Industries (CNSX:GTII) have almost doubled since June 2018, and this stock should trade higher once pot is legalized south of the border.

Green Thumb is a multi-state operator and has a large presence in the states of Illinois and Nevada. Last week, five states in the U.S. voted on marijuana legalization (medical or recreational or both), and this development drove shares of GTII higher.

Green Thumb Industries is all those things that Aurora Cannabis isn’t. GTII is growing sales at a fast pace and is EBITDA positive. The company has a presence in 12 states in the U.S. and is well positioned to go after the rapidly expanding market in the country.

The cannabis markets in Illinois and Nevada are forecast to be multi-billion-dollar ones, which mean investors can expect GTII sales to continue to grow higher in the upcoming decade.

In the June quarter, Green Thumb increased sales by 167% to $119.6 million while EBITDA soared close to 1,500% to $35.4 million. Green Thumb has licences to open 96 retail stores and currently has a portfolio of 49 stores in 12 states.

GTII stock is valued at a market cap of US$4.3 billion indicating a forward price-to-sales multiple of 8.7, which is not too expensive given the company is expected to more than double its sales in 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »